BioSpace News Archive

The data has been collected through extensive primary and secondary research and is validated by experts in the industry.

The data has been collected through extensive primary and secondary research and is validated by experts in the industry.

The industry analysis report is considered a valuable source of information about the global Fluoxetine industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

Global Blood Therapeutics, Inc. announced that it will participate in a virtual fireside chat at the Guggenheim Genomic Medicines & Rare Disease Day on Friday, April 1, 2022, at 12:00 p.m. E.T.

Sight Sciences, Inc. (Nasdaq: SGHT), today announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI® Surgical System with higher volume as a safe and effective standalone treatment option, compared to implantation of iStent inject®, in lowering IOP in adult patients with open-angle glaucoma.

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Inhibrx, Inc. announced that data from INBRX-121 and INBRX-130 will be presented at the 2022 American Association for Cancer Research Annual Meeting to be held April 8th- 13th, 2022 in New Orleans, LA.

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2021.

Metagenomi, a genetic medicines company with a versatile portfolio of next-generation gene editing tools, announced that it will present at two upcoming investor conferences.

MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), today provided an update after a recent meeting with the U.S. Food Drug Administration (FDA) to discuss the pursuit of a marketing authorization for zandelisib, a phosphatidylinositol-3-kinase (“PI3K”) inhibitor drug candidate, via the accelerated approval pathway under 21 CFR Part 314.500, Subpart H, based on data generated by the single arm Phase 2 TIDAL study.